Abstract
Circulating tumour cells (CTCs) are a source of prognostic and predictive biomarkers across multiple cancers, including head and neck squamous cell carcinoma (HNSCC). Characterisation of CTCs has historically focussed on RNA expression. Although a powerful approach, important cellular changes can occur in the absence of transcriptional modification through processes such as alterations in protein stability, subcellular localisation or post-translational modification such as phosphorylation. To increase the number of protein markers that can be measured per cell we developed and validated a protocol to apply mass cytometry to CTCs enriched from blood using Parsortix technology.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
